The global adoption of artemisinin-based combination therapies (ACTs) in the early 2000s
heralded a new era in effectively treating drug-resistant Plasmodium falciparum malaria …

A marked decrease in malaria-related deaths worldwide has been attributed to the
administration of effective antimalarials against Plasmodium falciparum, in particular …

Background Partial artemisinin resistance is suspected if delayed parasite clearance (ie,
persistence of parasitaemia on day 3 after treatment initiation) is observed. Validated …

Abstract Background In Uganda, artemether-lumefantrine is recommended for malaria
treatment and sulfadoxine-pyrimethamine for chemoprevention during pregnancy, but drug …

Background Artemisinin and partner-drug resistance in Plasmodium falciparum are major
threats to malaria control and elimination. Triple artemisinin-based combination therapies …

Antimalarial drug resistance, in particular resistance to Plasmodium falciparum, challenges
the treatment and control of malaria. In this Review, we summarise evolving patterns of …

Understanding and controlling the spread of antimalarial resistance, particularly to
artemisinin and its partner drugs, is a top priority. Plasmodium falciparum parasites resistant …

Artemisinin partial resistance may facilitate selection of Plasmodium falciparum resistant to
combination therapy partner drugs. We evaluated 99 P. falciparum isolates collected in 2021 …

The worldwide use of artemisinin-based combination therapies (ACTs) has contributed in
recent years to a substantial reduction in deaths resulting from Plasmodium falciparum …

For more than five decades, Southeast Asia (SEA) has been fertile ground for the
emergence of drug-resistant Plasmodium falciparum malaria. After generating parasites …